All In Biotech

Drug Trial Radar · NCT07636811

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Aug 17, 2026

Primary completion

May 18, 2030

Study completion Jul 30, 2031

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month open-label treatment extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 39 months.

Conditions

  • Down Syndrome-Associated Alzheimer's Disease (DS-AD)

Interventions

  • MivelsiranDrug

    Mivelsiran will be administered intrathecally

  • PlaceboDrug

    Placebo will be administered intrathecally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs)Time frame: Up to 24 months

Locations

20 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Maitland, Florida · Recruiting

  • Clinical Trial Site

    Naples, Florida · Recruiting

  • Clinical Trial Site

    Fishers, Indiana · Not yet recruiting

  • Clinical Trial Site

    Indianapolis, Indiana · Recruiting

  • Clinical Trial Site

    Kansas City, Kansas · Recruiting

  • Clinical Trial Site

    St Louis, Missouri · Recruiting

  • Clinical Trial Site

    Cincinnati, Ohio · Recruiting

  • Clinical Trial Site

    Cincinnati, Ohio · Not yet recruiting

  • Clinical Trial Site

    Nashville, Tennessee · Not yet recruiting

  • Clinical Trial Site

    Nashville, Tennessee · Recruiting

  • Clinical Trial Site

    Beaumont, Texas · Recruiting

  • Clinical Trial Site

    Madison, Wisconsin · Not yet recruiting

  • Clinical Trial Site

    Madison, Wisconsin · Recruiting

  • Clinical Trial Site

    Barcelona, Spain · Recruiting

  • Clinical Trial Site

    Dos Hermanas, Spain · Recruiting

  • Clinical Trial Site

    Madrid, Spain · Recruiting

  • Clinical Trial Site

    Pamplona, Spain · Recruiting

  • Clinical Trial Site

    Seville, Spain · Recruiting

  • Clinical Trial Site

    Valencia, Spain · Recruiting

  • Clinical Trial Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.